microbiome among Irritable Bowel Syndrome patients and healthy individuals' (CO-MIC) study at 121 two time-points with a one-year interval between sampling. None of the individuals in this cohort 122 received antibiotics. All included patients and healthy subjects were adults. 123
124

Gut microbiota profiling by HITChip 125
The HITChip is a validated phylogenetic array produced by Agilent Technologies (Palo Alto, CA) and 126 developed at Wageningen University, The Netherlands [21, 22] . It contains over 4,800 127 oligonucleotides targeting the V1 and the V6 region of the 16S rRNA gene from 1,132 microbial 128 phylotypes present in the human gut [21] . DNA from fecal samples was isolated as previously 129 described [23] . The full-length 16S rRNA gene was amplified from fecal DNA, and PCR products 130
were further processed and hybridized to the microarrays as described previously [24] . Data 131 analyses were performed using R (www.r-project.org), including the microbiome package 132 (https://github.com/microbiome). Bacterial associations in the different patient groups and healthy 133 subjects were assessed using Principal Component Analysis (PCA) as implemented in CANOCO 5.0 134
[25]. Statistical testing for the differences in microbiota composition between ICU patients and 135 healthy subjects was performed by the non-parametric Mann-Whitney U test. All P-values were 136 corrected for false discovery rate (FDR) by the Benjamini and Hochberg method [26] , and corrected 137 P-values (q) below 0.05 were considered significant. 138 139
Quantification of E. coli by qPCR 140
qPCRs for the quantification of E. coli were performed with primers that were previously described 141
[27], using serial dilutions of genomic DNA of E. coli DH5α to generate a standard curve. Thequantification of 16S rRNA was performed with primers described in [28] . The PCR conditions were 143 identical to the qPCR conditions for the detection of mcr-1 (described above). 144 145 qPCR analysis of antibiotic resistance genes 146 qPCR analysis was performed using the 96.96 BioMark™ Dynamic Array for Real-Time PCR 147 (Fluidigm Corporation, San Francisco, CA), according to the manufacturer's instructions, with the 148 exception that the annealing step in the PCR was held at 56°C. Fecal DNA was first subjected to 14 149 cycles of Specific Target Amplification using a 0.18 μM mixture of all primer sets, excluding the 16S 150 rRNA primer sets, in combination with the Taqman PreAmp Master Mix (Applied Biosystems), 151
followed by a 5-fold dilution prior to loading samples onto the Biomark array for qPCR. Thermal 152 cycling and real-time imaging was performed on the BioMark instrument, and Ct values were 153 extracted using the BioMark Real-Time PCR analysis software. 154
155
Target selection, primer design and primer validation 156
The primer set used in the qPCR assays covered 81 antimicrobial resistance genes (ARGs) of 14 157 resistance gene classes (Table S1 ). Primers were designed for the ARGs that are most commonly 158 detected in the gut microbiota of healthy individuals [14, 15] and clinically relevant ARGs, including 159 genes encoding extended spectrum β-lactamases (ESBLs), carbapenemases, and proteins involved 160 in vancomycin resistance. We also included 10 genes encoding transposases, and a gene encoding 161 an integrase as representatives of mobile genetic elements [29] . Seven of these genes were detected 162 by qPCR but no significant differences could be observed between patients and healthy subjects 163 (data not shown) and these are not further discussed in our manuscript. Primer design was 164 performed using Primer3 [30] with its standard settings with a product size of 80 -120 bp and aprimer melting temperature of 60°C. The universal primers for 16S rRNA genes were previously 166 described by Gloor et al. [28] . Forward and reverse primers were evaluated in silico for cross 167 hybridization using BLAST [31] and were cross-referenced against ResFinder [32] to ensure the 168 correct identity of the targeted genes. All primers that aligned with more than 10 nucleotides at 169 their 3' end to another primer sequence were discarded and redesigned. Additionally, all primer 170 sets were aligned to all resistance genes that were targeted in this PCR analysis to test for cross 171 hybridisation with genes other than the intended target resistance gene. Primers that aligned with 172 more than 10 nucleotides at their 3' end sequence with a non-target resistance gene were discarded 173 and redesigned. A reference sample consisting of pooled fecal DNA from different patients was 174 loaded in a series of 4-fold dilutions and was used for the calculation of primer efficiency. All 175 primers whose efficiency was experimentally determined to be between 80% and 120% were used 176 to determine the normalized abundance of the target genes. The detection limit on the Biomark 177 system was set to a CT value of 20, as recommended by the manufacturer. In addition, to assess 178 primer specificity we performed melt curve analysis using the Fluidigm melting curve analysis 179 software (http://fluidigm-melting-curve-analysis.software.informer.com/). All PCRs were 180 performed in triplicate and sample-primer combinations were only included in the analysis when all 181 triplicate reactions resulted in a CT-value below the detection limit. 182
After completion of the nanolitre-scale qPCR assays, the transferable colistin resistance gene mcr-1 183 was described [33] . To detect and quantify mcr-1, we developed primers (qPCR-mcr1-F: 5'-184 TCGGACTCAAAAGGCGTGAT-3' and qPCR-mcr1-R: 5'-GACATCGCGGCATTCGTTAT-3') for use in a 185 standard qPCR assay. The mcr-1 gene was synthesized based on the sequence described in [33] by 186
Integrated DNA Technologies (Leuven, Belgium) and used as a positive control in our assays. The 187 qPCR was performed using Maxima SYBR Green/ROX qPCR Master Mix (Thermo Scientific, Leusden, 188
The Netherlands) and a StepOnePlus instrument (Applied Biosystems, Nieuwekerk a/d IJssel, The 
Microbiota dynamics in ICU patients and healthy subjects 204
Global changes in the gut microbiota of healthy subjects and ICU patients were visualized by 205
Principal Component Analysis (Fig. 1A) . The microbiota profiles of healthy subjects clustered 206 together, indicating that they had stable and broadly comparable microbiota profiles, which were 207 clearly distinct from the microbiota profiles of patients during and after ICU stay. These profiles 208 covered a larger area in the PCA plot, indicating that the differences in the microbiota composition 209 of patients were larger than in healthy subjects. Notably, the microbiota of several ICU patients (e.g. 210 #120, #169, #180, #43) was already distinct from the microbiota of the healthy subjects in the first 211 days of ICU hospitalization, indicating that ICU hospitalization has a rapid effect on the microbiota. 212
The diversity of the microbiota, as quantified by Shannon's diversity index, was significantly lower 213 in ICU patients compared to healthy subjects (5.90 ± 0.20 vs 5.19 ± 0.46, respectively; P < 0.001, 214
Student's t-test) . The diversity of the microbiota of ICU patients was highly dynamic (Fig. 1B) . 215
Several patients (#108, #163, #164, #165 and #169) experienced a rapid loss of diversity in the 216 first days of ICU stay. In contrast, the diversity of the microbiota was more stable in healthy subjects 217 when comparing samples that were collected one year apart (Fig. 1C ). Compared to healthy 218 subjects, the microbiota of patients during ICU hospitalization was characterized by a significantly 219 higher abundance in the taxa Bacteroidetes and Bacilli: Enterococcus and a lower abundance of the 220 taxa Clostridium cluster IV and XIVa (Fig. 1D) . 221
We performed quantitative PCRs to accurately determine the abundance of E. coli, one of the 222 primary targets of SDD, in the gut microbiota of patients and healthy subjects (Fig. 2) . The 223 abundance of E. coli in samples of ICU patients was lower compared to the healthy subjects (p = 224 0.001; Mann-Whitney U test). Notably, upon cessation of SDD and transfer to a medium-care ward,the abundance of E. coli rebounded in one patient (#105) to levels surpassing those found in healthy 226
individuals. 227
During ICU stay, routine surveillance by conventional microbiological culture was performed on all 228
patients. E. coli could be cultured from six out of 73 rectal swabs that were collected during the 229 patients' ICU-stay. Five E. coli positive rectal swabs, of patients #43, #105, #108, #163, and #169, 230
were collected within one day of ICU admission, while the sixth positive swab (of patient #165) was 231 collected after nine days of ICU-stay. In addition, an E. coli strain from patient #105 with an ESBL-232 producing and tobramycin-resistant phenotype was isolated after ICU discharge, while the patient 233 was in a medium-care ward. The E. coli strains isolated during ICU stay were susceptible to 234 cephalosporins and aminoglycosides. All E. coli strains were susceptible to colistin. 235 236
Resistome dynamics in ICU patients and healthy subjects 237
A total of 46 unique ARGs conferring resistance to 12 different classes of antimicrobials were 238 detected in the DNA isolated from fecal samples of hospitalized patients and healthy subjects (Fig.  239   S2 ). The number of detected resistance genes per sample ranged between 6 and 38. Eleven 240 resistance genes were detected in >80% of healthy subjects and critically ill patients. This highly 241 prevalent set of resistance genes included tetracycline resistance genes (tetO, tetQ, tetM, tetW), two 242 aminoglycoside resistance genes (aph(3′)-III and an aadE-like gene), the bacteroidal β-lactam 243 resistance gene cblA, and the macrolide resistance gene ermB. 244
Genes associated with major antibiotic resistance threats , including those identified by the Centers 245 for Disease Control, were relatively rare. Genes encoding for extended-spectrum beta-lactamases 246 (ESBLs) were not detected in healthy subjects. In two ICU patient samples (#105C and #108C), 247 however, the ESBL genes blaCTX-M and blaDHA, respectively, could be detected. Sample #105C wascollected after ICU discharge and cessation of SDD, while sample #108C was collected after 12 days 249 of ICU hospitalization and SDD treatment. The carbapenemase blaKPC was detected in a single patient 250 (patient #180), but only in the first sample (collected after 5 days in the ICU) and not in the second 251 sample, which was collected after 16 days of ICU hospitalization. No other ESBL-or carbapenemase-252 producing strains were isolated from the patients during ICU hospitalization. Other Enterobacterial 253 β-lactamases were found to be widespread in our resistome analysis. The blaAMPC β-lactamase was 254 present in 37% of samples, with nine of ten patients and eight of ten healthy subjects having 255 detectable levels of blaAMPC at one or more sampling points. The blaTEM β-lactamase was present in 256 26% of samples, corresponding with five of ten patients and four of ten healthy subjects in which 257 this gene was detectable at one or more sampling points. None of the samples were positive for the 258 carbapenemases blaNDM and blaOXA, or the transferable colistin resistance gene mcr-1 (data not 259 shown). Among resistance genes that are associated with Gram-positive pathogens, the 260 staphylococcal methicillin resistance gene mecA was detected in 13 samples from eight of ten 261 patients, but not in samples of healthy subjects. The vancomycin resistance gene vanB was present 262 in 5 samples from three of ten patients and six samples from four of ten healthy subjects. 263
A comparison of the abundance of individual ARGs in samples that were collected during ICU stay, 264 versus samples from healthy subjects, revealed that four ARGs (aac(6')-Ii, ermC, qacA, tetQ) were 265 significantly more abundant in ICU patients, while two ARGs (catA and tetW) were significantly 266 more abundant in healthy individuals (Fig. 3) . supports previous studies which found that SDD is successful in suppressing outgrowth of E. coli in 287 the gut microbiota of ICU patients [8,9], corresponding to the original aim of SDD [7] . 288
Notably, levels of E. coli increased again after ICU-discharge in two of patients, reaching levels in the 289 gut similar to, or even surpassing, those in healthy individuals. These findings suggest that a rapid 290 regrowth or recolonization of the intestinal tract by E. coli, and possibly other aerobic Gram-291 negative bacteria, occurs upon cessation of prophylactic antibiotic therapy. It remains to be 292 determined whether rapid post-ICU recolonization by E. coli increases the risk for infections with 293 this bacterium. Yet, in the only prospective evaluation on the post-ICU effects of SDD, the 294 implementation of SDD was not associated with higher infection rates after ICU discharge [40] . 295
The qPCR-based analysis of the resistome confirms previous metagenomic studies, in showing that 296 tetracycline and aminoglycoside resistance genes and bacteroidal β-lactamases are widespread in 297 the human intestinal microbiota [14, 15, 18, 20] . Four resistance genes (aac(6')-Ii, ermC, qacA, tetQ) 298
were significantly more abundant among ICU patients than in healthy subjects. The aac(6')-Ii gene is 299 a specific chromosomal marker for the nosocomial pathogen Enterococcus faecium and provides 300 low-level resistance to aminoglycosides [41] . Its high abundance in ICU patients is in line with the 301 increased levels of enterococci in the microbiota of the patients. The increased abundance of the 302 macrolide resistance gene ermC may have been selected for by the use of low doses of the macrolide 303 erythromycin, which was used as an agent to accelerate gastric emptying during ICU stay in six 304 patients. The increased abundance of tetQ in the gut microbiota of ICU patients may reflect the 305 higher abundance of Bacteroidetes in ICU patients versus healthy subjects, as tetQ is widely 306 distributed on conjugative transposons in this phylum [42] . Finally, the qacA gene confers resistance 307 to a number of disinfectants, including the biguanidine compound chlorhexidine and the quaternary 308 ammonium compound benzalkonium chloride [43, 44] . Disinfectants are widely used in ICUs as 309 cleaning and infection control agents [45] and their use could select for qacA in the gut microbiota of 310
patients. 311
Two resistance genes (catA and tetW) were more abundant in healthy individuals than in ICU 312 patients. There is currently little information on the distribution of the catA gene among bacteria 313 associated with the human gut microbiota, but the gene was frequently found in human faeces in a 314 recent study set in low-income human habitats [46] . The tetracycline resistance gene tetW is 315 present in Gram-positive anaerobic gut commensals [47] . The gut bacteria that catA and tetW are 316 associated with, most likely members of Clostridium clusters IV and XIVa, are likely depleted duringICU-stay and SDD-treatment. 318
Although SDD improves survival of ICU-patients, its use remains controversial due to the perceived 319 risk for selection of antibiotic resistance among bacteria that populate the patient gut. In this study, 320
we were not able to include an ICU control group that was not treated with SDD, as this would be a 321 breach of clinical guidelines for ICU-patients in our country. It is notable, however, that we did not 322 find selection for high-risk antibiotic resistance genes (like ESBLs, carbapenemases or vancomycin 323 resistance genes) in SDD-treated patients. The increased abundance of the resistance genes aac(6')-324
Ii, ermC, qacA and tetQ in SDD-treated ICU patients in our study is -in our opinion -of limited 325 concern. The first three resistance genes contribute to resistance in enterococci, either to relatively 326 low concentrations of antibiotics (aac(6')-Ii) or to classes of antimicrobials that are of limited 327 relevance for the treatment of enterococcal infections (ermC and qacA). The tetQ gene provides 328 resistance to tetracyclines in Bacteroidetes, but this class of antibiotics is scarcely used for the 329 treatment of anaerobic infections [48] . Our data further support the ecological safety of SDD, at least 330 in settings with low levels of circulating antibiotic resistance, as it does not lead to selection for 331 clinically relevant antibiotic resistance phenotypes [36] . 332
In addition, our study illustrates the expediency of using culture-independent methods to monitor 333 the presence and abundance of antibiotic resistance genes. The qPCR platform used here enables 334 the rapid detection and quantification of antibiotic resistance genes in the gut microbiota of 335 patients. The detection of high-risk antibiotic resistance genes (encoding e.g. ESBLs, 336 carbapenemases or vancomycin resistance proteins) in the resistome of patients may lead to the 337 implementation of targeted antibiotic therapy or infection control measures to minimize the risk 338 for selection and spread of these resistance genes. 339
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